



## Novel Therapeutic Targets in Melanoma

Guest Editors:

**Dr. Stephane Rocchi**

INSERM U1065, Team 12, Centre  
Méditerranéen de Médecine  
Moléculaire, Université Côte  
d'Azur, Nice, France.

**Dr. Michaël Cerezo**

INSERM U1065, Team 12, Centre  
Méditerranéen de Médecine  
Moléculaire, Université Côte  
d'Azur, Nice, France.

Deadline for manuscript  
submissions:  
**closed (31 January 2022)**

### Message from the Guest Editors

Dear colleagues,

Melanoma is the deadliest form of skin cancer. During the last ten years, melanoma has been a figurehead for targeted therapies and immunotherapy development. Currently, the 5-year overall survival rate for BRAF-mutated patients treated with first-line therapies targeting BRAF<sup>V600E</sup> and MEK is only around 30 percent, and for patients treated with immunotherapies, it is around 40 percent for anti-PD1 alone and 50 percent for anti-PD1 plus anti-CTLA4. Unfortunately, even if targeted therapies and immunotherapies have seen huge progress, we have now arrived at a plateau.

In this Special Issue, we want to highlight different new potential strategies regarding the melanoma cells themselves and the tumor microenvironment to bypass resistance and smash this glass ceiling.

Dr. Stephane Rocchi

Dr. Michaël Cerezo

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)